Single Use Bioreactors Market Size, Share, Growth, and Industry Analysis, By Type (Wave-induced Motion Single Use Bioreactors,Stirred Single Use Bioreactors,Others), By Application (R&D,Biopharmaceutical Manufacturers), Regional Insights and Forecast to 2035

Single Use Bioreactors Market Overview

The global Single Use Bioreactors Market size is projected to grow from USD 7591.81 million in 2026 to USD 8831.55 million in 2027, reaching USD 29615.18 million by 2035, expanding at a CAGR of 16.33% during the forecast period.

Single use bioreactors (SUBs) represent disposable cultivation systems utilizing pre-sterilized polymer bags instead of traditional stainless steel vessels. In 2023, global SUB system shipments exceeded 800 units, with typical bag volumes ranging from 50 L to 2,000 L deployed across R&D and manufacturing.

In the United States, the single use bioreactors market is among the most mature globally, with over 300 SUB systems installed in biologics and cell therapy facilities by 2023. More than 45% of U.S. CDMOs offer single use manufacturing capacity, ranging from 200 L to 2,000 L.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 55% increase in biologics pipelines using flexible manufacturing platforms
• Major Market Restraint: 32% of users cite concerns over extractables/leachables in polymer bags
• Emerging Trends: 28% of new SUB releases integrate inline sensors or modular automation
• Regional Leadership: North America commands ~35% share of installed SUB systems globally
• Competitive Landscape: Top 5 suppliers control ~65% of SUB system shipments
• Market Segmentation: Stirred SUBs occupy ~70% share, wave motion ~20%, others ~10%
• Recent Development: In 2024, a new 2,000 L SUB system reduced footprint by 15%

Single Use Bioreactors Market Latest Trends

Recent trends in the Single Use Bioreactors Market point toward increasing emphasis on process intensification, smaller batch sizes, and modular biomanufacturing. In 2024, approximately 45% of new SUB units shipped were sized >1,000 L, reflecting demand for mid-scale commercial bioprocessing. The adoption of integrated inline sensors (pH, dissolved oxygen, Raman spectroscopy) is now standard in ~30% of new systems, enabling real-time monitoring and reducing sample burdens.

Single Use Bioreactors Market Dynamics

The dynamics of the Single Use Bioreactors Market are heavily influenced by global shifts in biologics manufacturing and the increasing preference for flexible, contamination-free production systems. The market is expanding rapidly as more than 60% of newly built biologics facilities now integrate single use bioreactors (SUBs) in their upstream processes.

DRIVER

"Surge in biologics, cell & gene therapy pipelines"

As of 2023, over 2,500 biologics and 750 cell/gene therapy candidates are under active development globally. Many of these require flexible, small-batch manufacturing that SUBs facilitate. The ability of SUBs to reduce CAPEX by 25–40% over stainless steel systems and eliminate cleaning validation costs appeals strongly to emerging biotech firms.

RESTRAINT

"Concerns over extractables, compatibility, and waste disposal"

One of the principal obstacles in SUB adoption is the risk of polymer leachables and extractables, which may interfere with biologics quality. In surveys, ~32% of potential users cite extractables risk as their top concern. Compatibility issues with novel cell lines or media can lead to batch failures, making validation burdensome.

OPPORTUNITY

"Hybrid bioprocessing, modular facilities, emerging markets"

Hybrid facilities combining both single use and stainless systems present opportunities to de-risk transition while leveraging SUB flexibility. Modular factories—preassembled, mobile, and skid-mounted—allow rapid facility deployment; in 2024, over 20 modular units featuring SUB systems were commissioned globally.

CHALLENGE

"Scalability, standardization, regulatory validation"

Scaling SUB technology from 2,000 L to 10,000 L while maintaining mixing and oxygen transfer is challenging—venturi mixing and impeller designs face hydrodynamic limits. Lack of standardization across suppliers (bag geometries, connectors, sensor interfaces) imposes integration burdens on users.

Single Use Bioreactors Market Segmentation

The Single Use Bioreactors Market segmentation is typically defined by Type (Wave-induced motion SUBs, Stirred SUBs, Others) and Application (R&D / process development, Biopharmaceutical manufacturing). Stirred SUBs currently dominate with ~70% share due to superior mixing and oxygen transfer, while wave SUBs capture ~20% in gentle shear applications.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Wave-Induced Motion Single Use Bioreactors: Wave or rocking motion SUBs use a pillow-style disposable bag mounted on a rocking platform to achieve mixing and gas transfer. These systems are gentle in shear, making them suitable for sensitive mammalian cells or viral vector production. In 2023, wave SUB shipments represented ~20% of new SUB system orders.

The Wave-Induced Motion Single Use Bioreactors segment is estimated at USD 1,305.2 million in 2025 (≈ 20.0% share) and is projected to reach approximately USD 5,091.6 million by 2034, expanding steadily at a CAGR of 16.33 %, driven by the growing adoption of compact, energy-efficient, and easily scalable bioprocessing systems for cell culture and vaccine manufacturing applications across biopharmaceutical facilities globally.

Top 5 Major Dominant Countries in the Wave-Induced Segment

• United States: The United States commands the largest share of the wave-induced single use bioreactors market, valued at approximately USD 318.8 million in 2025, accounting for nearly 24.4 % of the total segment, and projected to grow at a CAGR of 16.33 %. The country’s leadership is attributed to its well-established biopharmaceutical manufacturing infrastructure, where more than 70 % of large-scale biologics facilities have adopted wave-motion systems to enhance process flexibility and reduce cleaning validation times.
• China: China’s wave-induced single use bioreactors market is projected to reach approximately USD 261.0 million in 2025, representing nearly 20.0 % of the global segment share, with growth continuing at a CAGR of 16.33 %. The rapid expansion of biopharma capacity—supported by over 150 new biomanufacturing projects initiated since 2021—and increasing government incentives for single-use technology adoption have positioned China as one of the fastest-emerging markets for disposable bioprocessing systems.
• Germany: Germany’s contribution to the wave-induced single use bioreactors segment is valued at around USD 130.5 million in 2025, holding an estimated 10.0 % global market share and expected to expand further at a CAGR of 16.33 %. The country’s strong foothold stems from its advanced bioprocess R&D ecosystem, comprising over 40 dedicated cell culture facilities, and its focus on integrating automated wave systems to support continuous and small-batch vaccine production.
• Japan: Japan’s wave-induced single use bioreactors market is anticipated to be valued at nearly USD 94.0 million in 2025, accounting for approximately 7.2 % of the total segment, and expected to grow consistently at a CAGR of 16.33 %. The nation’s emphasis on precision bioprocessing technologies, coupled with its aging population and increased vaccine demand—surpassing 300 million annual doses—continues to drive the installation of compact, flexible wave reactor platforms in R&D and pilot-scale applications.
• United Kingdom: The United Kingdom’s wave-induced single use bioreactors market is projected at approximately USD 75.6 million in 2025, capturing around 5.8 % of the segment share, and growing steadily at a CAGR of 16.33 %. The market’s growth is supported by strong investment from national biomanufacturing innovation hubs and the expansion of contract development and manufacturing organizations (CDMOs), where nearly 60 % of new facilities are incorporating wave-based SUB systems for enhanced production efficiency and lower contamination risk.

Stirred Single Use Bioreactors: Stirred SUBs dominate the market, accounting for around 70% of units, due to robust mixing, high oxygen transfer, and scalability. These systems integrate a disposable bag with impellers inside the bag and external motor drive. Typical volumes range from 100 L to 2,000 L, with new models extending to 4,000 L.

The Stirred Single Use Bioreactors segment is projected at USD 3,263.0 million in 2025 (≈ 50.0% share) and is expected to reach USD 12,728.9 million by 2034, expanding at a consistent CAGR of 16.33 %.

Top 5 Major Dominant Countries in the Stirred Segment

• United States: The United States represents the most mature market in the stirred single use bioreactors category, valued at approximately USD 796.9 million in 2025, accounting for 24.4 % of the global share, and expanding at a CAGR of 16.33 %. This dominance is underpinned by over 60 % of U.S. biologics manufacturers integrating stirred SUB systems into large-scale production, enhancing yields and shortening production cycles across both clinical and commercial facilities.
• China: China’s stirred single use bioreactors market is estimated at USD 652.6 million in 2025, with an overall 20.0 % share of the global segment, growing at a CAGR of 16.33 %. The nation’s booming biopharmaceutical manufacturing infrastructure—backed by government incentives and investments exceeding USD 3 billion in the past three years—has accelerated the transition from stainless-steel systems to flexible, disposable reactor platforms.
• Germany: Germany’s stirred single use bioreactors segment is valued at approximately USD 326.3 million in 2025, representing 10.0 % of the global market, with a steady CAGR of 16.33 % through 2034. The German market’s strength is anchored in its precision engineering, automation advancements, and the presence of over 50 GMP-certified bioproduction sites deploying stirred SUBs for biologics, enzymes, and vaccines manufacturing.
• Japan: Japan’s stirred single use bioreactors market is forecasted to reach USD 234.9 million in 2025, comprising roughly 7.2 % of the global segment, and expanding at a CAGR of 16.33 %. The growth is propelled by the country’s commitment to personalized medicine, where more than 45 % of domestic pharma R&D facilities utilize stirred SUB systems to optimize cell growth and minimize contamination.
• United Kingdom: The United Kingdom’s stirred single use bioreactors market is projected at USD 189.2 million in 2025, accounting for about 5.8 % of the total share, with expansion at a CAGR of 16.33 %. The UK’s CDMO sector has been instrumental, as more than 30 new biologics manufacturing projects since 2022 have incorporated stirred SUB units to enhance upstream process efficiency and reduce turnaround time.

Others (Hybrid / Specialty): The Others category includes bubble-column SUBs, vertical disc single use types, and hybrid systems merging mechanical and wave mixing principles. Though currently ~10% of shipments, this segment is gaining traction in niche applications requiring unique mixing or gas transfer profiles.

The Others (Hybrid / Specialty Single Use Bioreactors) segment is valued at USD 1,957.9 million in 2025 (≈ 30.0% share) and projected to reach approximately USD 7,637.4 million by 2034, reflecting a strong CAGR of 16.33 %.

Top 5 Major Dominant Countries in the Others Segment

• United States: The United States dominates the hybrid and specialty single use bioreactors market, estimated at USD 477.4 million in 2025, representing 24.4 % of the segment, and growing consistently at a CAGR of 16.33 %. The integration of hybrid systems in over 70 leading biopharma facilities allows flexible batch management, lower cleaning costs, and faster turnaround for clinical-scale production.
• China: China’s others segment market is projected at USD 391.6 million in 2025, accounting for roughly 20.0 % of global market share, advancing at a CAGR of 16.33 %. Increasing investment in modular biomanufacturing and the establishment of 25 new biotech industrial parks since 2021 have rapidly driven adoption of hybrid SUB technologies across vaccine and biosimilar production.
• Germany: Germany’s hybrid single use bioreactors market is valued at USD 195.8 million in 2025, maintaining around 10.0 % global share, with steady growth at a CAGR of 16.33 %. The country’s focus on flexible bioprocessing lines has resulted in the deployment of over 30 pilot-scale hybrid facilities emphasizing automation, digital integration, and sustainable materials.
• Japan: Japan’s hybrid and specialty SUB market stands at USD 141.0 million in 2025, contributing approximately 7.2 % of total segment share, with expansion at a CAGR of 16.33 %. With over 20 major biopharmaceutical firms investing in advanced hybrid bioprocessing capabilities, Japan continues to reinforce its regional presence in precision biologics production.
• United Kingdom: The United Kingdom’s others segment market is projected at USD 113.6 million in 2025, holding about 5.8 % of the segment share, and expanding at a CAGR of 16.33 %. The country’s surge in biomanufacturing partnerships and hybrid facility projects—exceeding USD 800 million in new investments since 2023—is enhancing capacity for next-generation biologics and gene therapy manufacturing.

BY APPLICATION

R&D / Process Development: In R&D and process development, single use bioreactors are widely used for cell line screening, media optimization, scale-down modeling, and fed-batch/perfusion method development. These units typically range from 2 L to 100 L, with parallel arrays of ≥12 units common in development labs. In 2024, over 60% of SUB usage was in R&D settings, reflecting early-stage adoption.

The R&D / Process Development application segment is valued at USD 3,913.7 million in 2025 (≈ 60.0% share) and is anticipated to reach approximately USD 15,274.7 million by 2034, progressing at a consistent CAGR of 16.33 %.

Top 5 Major Dominant Countries in the R&D Application

• United States: The United States represents the largest R&D application base in the single use bioreactors market, valued at around USD 953.1 million in 2025, accounting for 24.4 % of global share, expanding steadily at a CAGR of 16.33 %. The U.S. dominates this segment through over 400 active biologics R&D programs and 120 specialized facilities using SUBs for high-throughput process screening and scalable experimental design.
• China: China’s R&D-related single use bioreactor market is estimated at USD 782.7 million in 2025, constituting approximately 20.0 % of the global share, advancing at a CAGR of 16.33 %. The surge is fueled by over 200 newly established biotechnology research hubs across major provinces, where modular, single use setups accelerate process development cycles and reduce technology transfer time by up to 25 %.
• Germany: Germany’s share in the R&D segment stands at USD 391.4 million in 2025, representing nearly 10.0 % of global market share, with expansion at a CAGR of 16.33 %. Supported by over 50 university-affiliated research bioprocess labs, Germany’s emphasis on process intensification and digital monitoring is driving wider adoption of single use reactors for pilot-scale trials.
• Japan: Japan’s R&D segment market is valued at approximately USD 282.8 million in 2025, reflecting a 7.2 % share globally, and progressing at a CAGR of 16.33 %. The country’s integration of advanced bioreactor control technologies into over 80 national R&D centers underlines its focus on accelerating innovation in gene therapy and personalized medicine.
• United Kingdom: The United Kingdom’s R&D-based single use bioreactor market is projected at USD 227.5 million in 2025, comprising about 5.8 % of the segment share, with a CAGR of 16.33 %. The presence of multiple biotech clusters across Oxford, Cambridge, and London—housing over 150 R&D institutes—continues to support SUB adoption for early-stage drug discovery and prototype vaccine development.

Biopharmaceutical Manufacturers: In biopharmaceutical manufacturing, SUBs are employed from pilot to commercial batches, particularly for small-to-mid volume biologics, vaccines, and gene therapy. Typical bag sizes from 500 L to 2,000 L are used in pilot plants, with some facilities deploying multiple units in parallel to reach required volumes.

The Biopharmaceutical Manufacturing application segment is valued at USD 2,612.4 million in 2025 (≈ 40.0% share) and projected to reach USD 10,183.2 million by 2034, expanding consistently at a CAGR of 16.33 %.

Top 5 Major Dominant Countries in the Biopharmaceutical Manufacturing Application

• United States: The United States dominates the biopharmaceutical manufacturing application, valued at around USD 636.7 million in 2025, accounting for 24.4 % of total market share, and expanding at a CAGR of 16.33 %. The U.S. is home to over 100 large-scale biologics plants, with nearly half converting to hybrid or fully disposable single use bioreactor systems for advanced cell culture applications.
• China: China’s biopharmaceutical manufacturing segment is valued at USD 522.5 million in 2025, representing roughly 20.0 % share, with a consistent CAGR of 16.33 %. More than 45 new biologics manufacturing facilities established since 2020 have integrated single use technology to meet local and export-oriented vaccine and biosimilar demand.
• Germany: Germany’s biopharmaceutical manufacturing market stands at USD 261.2 million in 2025, equating to 10.0 % global share, growing at a CAGR of 16.33 %. Germany’s biologics output—now exceeding USD 20 billion annually in product value equivalents—relies on scalable stirred SUBs and hybrid systems for multi-product production lines.
• Japan: Japan’s biomanufacturing application market is forecasted at USD 189.3 million in 2025, accounting for 7.2 % global share, with steady growth at a CAGR of 16.33 %. The increasing domestic production of regenerative therapies and monoclonal antibodies—supported by over 40 advanced cleanroom facilities—continues to boost SUB deployment in industrial-scale bioprocessing.
• United Kingdom: The United Kingdom’s biopharmaceutical manufacturing segment is valued at USD 152.1 million in 2025, representing about 5.8 % of global market share, and advancing at a CAGR of 16.33 %. The UK’s CDMO expansion strategy—adding over 15 new GMP-compliant production sites since 2022—has made SUBs a preferred choice for flexible batch operations and high-purity biologics manufacturing.

Regional Outlook for the Single Use Bioreactors Market

The Single Use Bioreactors Market is experiencing a robust global expansion, with significant regional variations in adoption, infrastructure investment, and technological maturity. Across all major regions, demand for flexible, disposable bioprocessing systems is increasing rapidly, fueled by growth in biologics, biosimilars, vaccines, and personalized medicines.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America leads the Single Use Bioreactors Market, accounting for approximately 35% share of world SUB installations. The U.S. houses the majority of top-tier biopharma and CDMOs, and in 2023 more than 300 SUB systems were installed across U.S. facilities. Several large-scale modular plants in the U.S. choose modular SUB suites to reduce build-out time by 20%.

The North America Single Use Bioreactors Market is valued at approximately USD 2,284.1 million in 2025 (≈ 35.0% global share) and is projected to reach around USD 8,960.3 million by 2034, advancing at a strong CAGR of 16.33 %.

North America – Major Dominant Countries in the “Single Use Bioreactors Market”

• United States: The United States leads North America’s single use bioreactors market, valued at approximately USD 1,858.2 million in 2025, accounting for nearly 81.4 % of the regional share, and advancing at a CAGR of 16.33 %. The country’s infrastructure of over 150 biologics plants and consistent adoption in monoclonal antibody production ensures sustained leadership across both commercial and academic sectors.
• Canada: Canada’s single use bioreactors market is estimated at USD 228.4 million in 2025, representing about 10.0 % of North America’s total, and growing at a CAGR of 16.33 %. Government-backed initiatives, such as national vaccine manufacturing programs, have resulted in over 20 new SUB-equipped facilities since 2022.
• Mexico: Mexico’s market value for single use bioreactors stands at USD 114.2 million in 2025, approximately 5.0 % of the region’s share, expanding at a CAGR of 16.33 %. Growing pharmaceutical outsourcing activities and local biotech investments are key enablers of adoption.
• Cuba: Cuba’s emerging biomanufacturing landscape positions its single use bioreactors market at USD 45.7 million in 2025, around 2.0 % regional share, expanding at a CAGR of 16.33 %, supported by state-funded vaccine programs.
• Panama: Panama holds an estimated USD 22.8 million market value in 2025, constituting roughly 1.0 % of North American demand, and expanding at a CAGR of 16.33 %, driven by regional pharmaceutical partnerships and logistics support.

EUROPE

Europe commands a strong position in the SUB market, representing around 25–30% of installations across major pharmaceutical and academic centers. Germany, France, UK, Switzerland, and the Netherlands are core adopters. In 2024, Europe approved over 12 monoclonal antibodies, boosting biologics production demands. European CDMOs in Germany and the UK increasingly adopt SUB-based modular suites across 100+ facilities.

The Europe Single Use Bioreactors Market is valued at USD 1,631.5 million in 2025 (≈ 25.0% global share) and expected to reach USD 6,393.0 million by 2034, maintaining a stable CAGR of 16.33 %.

Europe – Major Dominant Countries in the “Single Use Bioreactors Market”

• Germany: Germany leads the European market with an estimated USD 407.9 million in 2025, representing 25.0 % of regional share, and expanding at a CAGR of 16.33 %. Its 50+ GMP-certified facilities make it a regional hub for single use bioprocessing in vaccines and monoclonal antibodies.
• United Kingdom: The United Kingdom’s single use bioreactors market stands at USD 326.3 million in 2025, capturing 20.0 % share, with a CAGR of 16.33 %. Over 35 CDMOs now rely on SUB-based production suites for contract biologics manufacturing.
• France: France holds an estimated USD 244.7 million in 2025, accounting for about 15.0 % of European share, with a CAGR of 16.33 %. The French biotech innovation fund exceeding EUR 3.5 billion supports new facility expansion and automation integration.
• Italy: Italy’s single use bioreactors market is valued at USD 163.2 million in 2025, equal to 10.0 % of the regional share, and growing at 16.33 % CAGR. The country’s biologics R&D expansion across Lombardy and Lazio regions drives steady demand.
• Spain: Spain’s market value for SUB systems stands at USD 156.3 million in 2025, roughly 9.6 % of Europe’s total, and advancing at a CAGR of 16.33 %. Spain’s push for sustainable single use materials is accelerating technology adoption.

ASIA-PACIFIC

Asia-Pacific is emerging as the fastest growth region for SUB adoption, currently capturing approximately 20–25% of new installations. China, India, Japan, South Korea, and Singapore account for the bulk of this growth. In 2023, China alone commissioned >50 SUB-based bioprocessing suites, with domestic suppliers beginning to compete in SUB system manufacturing.

The Asia Single Use Bioreactors Market is valued at USD 1,307.2 million in 2025 (≈ 20.0% global share) and projected to reach around USD 5,114.4 million by 2034, registering a steady CAGR of 16.33 %.

Asia – Major Dominant Countries in the “Single Use Bioreactors Market”

• China: China dominates the Asian market with an estimated USD 326.8 million in 2025, accounting for 25.0 % of regional share, growing at a CAGR of 16.33 %. China’s 50+ SUB-equipped factories underscore its leadership in vaccine and biosimilar manufacturing.
• India: India’s market value is USD 261.4 million in 2025, representing 20.0 % regional share, with a CAGR of 16.33 %. National biotech investments exceeding USD 2 billion have fueled a wave of single use adoption across vaccine production.
• Japan: Japan’s single use bioreactors market totals USD 94.1 million in 2025, comprising 7.2 % of regional share, and growing at 16.33 % CAGR. Japan’s 40+ precision bioprocessing labs continue to emphasize hybrid single use integration.
• South Korea: South Korea holds USD 85.5 million in 2025, or 6.5 % of the Asian market, with a CAGR of 16.33 %. Its dominance in cell therapy manufacturing has led to rapid adoption of automated SUB systems.
• Australia: Australia’s single use bioreactors market is valued at USD 52.3 million in 2025, roughly 4.0 % of the regional share, and increasing at 16.33 % CAGR, driven by expanding CDMO and clinical-stage biopharma facilities.

MIDDLE EAST & AFRICA

Middle East & Africa (MEA) currently hold a modest share (~5%) of the global SUB market but show significant emerging potential. In the Gulf Cooperation Council (GCC) states, nations such as UAE, Saudi Arabia, and Qatar are establishing biotech hubs and investing in vaccine and biologics capacity. Some countries plan SUB-enabled facilities to reduce import reliance, with 3 planned plants in GCC by 2025 specifying SUB frameworks.

The Middle East and Africa (MEA) Single Use Bioreactors Market is estimated at USD 32.6 million in 2025 (≈ 0.5% share) and projected to reach USD 127.3 million by 2034, rising steadily at a CAGR of 16.33 %.

Middle East and Africa – Major Dominant Countries in the “Single Use Bioreactors Market”

• United Arab Emirates: The UAE leads MEA’s market with USD 9.8 million in 2025, accounting for 30.0 % of regional share, growing at 16.33 % CAGR, supported by national biotech cluster investments exceeding USD 500 million.
• Saudi Arabia: Saudi Arabia’s market is valued at USD 6.3 million in 2025, representing 19.4 % of regional share, and expanding at 16.33 % CAGR, with three new SUB-enabled vaccine facilities under Vision 2030.
• South Africa: South Africa’s single use bioreactors market totals USD 4.7 million in 2025, comprising 14.5 % share, growing at 16.33 % CAGR. Local vaccine production initiatives at the BioVac Institute are fueling increased adoption.
• Egypt: Egypt holds USD 3.7 million in 2025, representing 11.3 % of the region, and expanding at 16.33 % CAGR. Strategic collaborations with European biotechs are enabling SUB technology transfer for biosimilar production.
• Morocco: Morocco’s market stands at USD 3.2 million in 2025, capturing 9.7 % share, and rising at 16.33 % CAGR, backed by government-funded bio-incubator programs across Casablanca and Rabat.

List of Top Single Use Bioreactors Companies

• Merck Millipore
• Amprotein
• Finesse
• PBS Biotech
• Celltainer
• Pall (Danaher)
• Applikon
• Kuhner
• Eppendorf
• GE Healthcare
• Thermo Fisher

Sartorius / Stedim Biotech: leads due to broad SUB system portfolio, strong partnerships, and global installations in over 150 facilities.

Merck Millipore (Merck KGaA): ranks second, with extensive polymer film, assembly, and SUB system integration in 100+ contract manufacturing units.

Investment Analysis and Opportunities

Investment trends in single use bioreactors are accelerating, with life science venture funding into bioprocessing rising by over 35% year-on-year in 2023–2024. Biopharma companies and CDMOs are targeting modular SUB facilities with capacities spanning 200 L to 2,000 L, enabling flexible expansion without huge capital outlays.

New Product Development

Recent innovations in SUB design emphasize sensor integration, film optimization, and modular deployability. In 2024, a leading supplier released a 1,500 L SUB bag with enhanced barrier film reducing extractables by 30%.

Five Recent Developments

• In March 2024, Getinge AB launched the Single-Use Production Reactor (SUPR) system in 50 L and 250 L sizes to expand its SUB portfolio.
• In April 2023, Merck KGaA introduced the Ultimus polymer film for process containers, enhancing durability and reducing leak risk.
• In 2024, a prominent CDMO integrated inline Raman spectroscopy sensors into 1,000 L SUB systems for metabolite monitoring.
• In late 2024, a new microfluidic mixing SUB bag was released, reducing mixing time by 15% over standard designs.
• In early 2025, a facility retrofit converted four stainless steel reactors to hybrid SUB operation, cutting changeover times by 20%.

Report Coverage of Single Use Bioreactors Market

This Single Use Bioreactors Market Report provides a full and structured analysis, encompassing industry background, segmentation, regional and country-level insights, competitive mapping, innovations, and investment outlook. It spans three SUB types (wave-induced, stirred, and hybrid/other) and two application categories (R&D / process development; biopharmaceutical manufacturing).

Single Use Bioreactors Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 7591.81 Million in 2026
Market Size Value By	USD 29615.18 Million by 2035
Growth Rate	CAGR of 16.33% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Wave-induced Motion Single Use Bioreactors Stirred Single Use Bioreactors Others By Application : R&D Biopharmaceutical Manufacturers
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample